Chinese pharmaceutical company Sinopharm will start the third phase of a COVID-19 vaccine clinical trial in Peru. Around 12,000 vaccines already arrived in Lima. Phase three of the trial will include 6,000 people between the ages of 18 and 75. Trials with thousands of participants allow researchers to gather data on the efficacy of vaccines to pass regulatory approvals.

The vaccine has been developed by China National Biotec Group (CNBG), a unit of the state giant China National Pharmaceutical Group, Sinopharm. According to Sinopharm, the vaccine is being tested in Bahrain and the United Arab Emirates, with further tests in Morocco and Argentina.